Besides statins, ezetimibe and PCSK9 inhibitors, lomitapide (an anti-ApoB therapy) was also approved in 2012–2013 as an adjunctive treatment for HoFH. The gene discussed is PCSK9; the disease is homozygous familial hypercholesterolemia.